411 related articles for article (PubMed ID: 27433923)
21. Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia.
Qu X; Davison J; Du L; Storer B; Stirewalt DL; Heimfeld S; Estey E; Appelbaum FR; Fang M
Epigenetics; 2015; 10(6):526-35. PubMed ID: 25996682
[TBL] [Abstract][Full Text] [Related]
22. Use of methylation profiling to identify significant differentially methylated genes in bone marrow mesenchymal stromal cells from acute myeloid leukemia.
Huang J; Liu Z; Sun Y; Zhong Q; Xu L; Ou R; Li C; Chen R; Yao M; Zhang Q; Liu S
Int J Mol Med; 2018 Feb; 41(2):679-686. PubMed ID: 29207054
[TBL] [Abstract][Full Text] [Related]
23. BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.
Vidal V; Robert G; Goursaud L; Durand L; Ginet C; Karsenti JM; Luciano F; Gastaud L; Garnier G; Braun T; Hirsch P; Raffoux E; Nloga AM; Padua RA; Dombret H; Rohrlich P; Ades L; Chomienne C; Auberger P; Fenaux P; Cluzeau T
Oncotarget; 2017 Jul; 8(29):47103-47109. PubMed ID: 28514758
[TBL] [Abstract][Full Text] [Related]
24. Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn-β and chemoresistance in acute myeloid leukemia.
Yang J; Xiao X; Li R; Li Z; Deng M; Zhang G
Cancer Biomark; 2016; 16(1):81-8. PubMed ID: 26835708
[TBL] [Abstract][Full Text] [Related]
25. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
[TBL] [Abstract][Full Text] [Related]
26. PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.
Duhoux FP; Ameye G; Montano-Almendras CP; Bahloula K; Mozziconacci MJ; Laibe S; Wlodarska I; Michaux L; Talmant P; Richebourg S; Lippert E; Speleman F; Herens C; Struski S; Raynaud S; Auger N; Nadal N; Rack K; Mugneret F; Tigaud I; Lafage M; Taviaux S; Roche-Lestienne C; Latinne D; Libouton JM; Demoulin JB; Poirel HA; ;
Br J Haematol; 2012 Jan; 156(1):76-88. PubMed ID: 22050763
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML.
Botezatu L; Michel LC; Helness A; Vadnais C; Makishima H; Hönes JM; Robert F; Vassen L; Thivakaran A; Al-Matary Y; Lams RF; Schütte J; Giebel B; Görgens A; Heuser M; Medyouf H; Maciejewski J; Dührsen U; Möröy T; Khandanpour C
Exp Hematol; 2016 Aug; 44(8):713-726.e14. PubMed ID: 27216773
[TBL] [Abstract][Full Text] [Related]
28. Promoter DNA methylation and expression levels of HOXA4, HOXA5 and MEIS1 in acute myeloid leukemia.
Musialik E; Bujko M; Kober P; Grygorowicz MA; Libura M; Przestrzelska M; Juszczyński P; Borg K; Florek I; Jakóbczyk M; Siedlecki JA
Mol Med Rep; 2015 May; 11(5):3948-54. PubMed ID: 25585874
[TBL] [Abstract][Full Text] [Related]
29. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome.
Wang H; Wang XQ; Xu XP; Lin GW
Leuk Res; 2010 May; 34(5):598-604. PubMed ID: 19853913
[TBL] [Abstract][Full Text] [Related]
30. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
[TBL] [Abstract][Full Text] [Related]
31. Expression of myeloperoxidase in acute myeloid leukemia blasts mirrors the distinct DNA methylation pattern involving the downregulation of DNA methyltransferase DNMT3B.
Itonaga H; Imanishi D; Wong YF; Sato S; Ando K; Sawayama Y; Sasaki D; Tsuruda K; Hasegawa H; Imaizumi Y; Taguchi J; Tsushima H; Yoshida S; Fukushima T; Hata T; Moriuchi Y; Yanagihara K; Miyazaki Y
Leukemia; 2014 Jul; 28(7):1459-66. PubMed ID: 24457336
[TBL] [Abstract][Full Text] [Related]
32. tp53-dependent G2 arrest mediator candidate gene, Reprimo, is down-regulated by promoter hypermethylation in pediatric acute myeloid leukemia.
Tao YF; Li ZH; Wang NN; Fang F; Xu LX; Pan J
Leuk Lymphoma; 2015; 56(10):2931-44. PubMed ID: 25629980
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
Duong VH; Padron E; Al Ali NH; Lancet JE; Hall J; Kwok B; Zhang L; Epling-Burnette PK; List AF; Komrokji RS
Ann Hematol; 2018 Feb; 97(2):247-254. PubMed ID: 29167940
[TBL] [Abstract][Full Text] [Related]
34. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
Walter MJ; Ding L; Shen D; Shao J; Grillot M; McLellan M; Fulton R; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Kandoth C; Baty J; Westervelt P; DiPersio JF; Mardis ER; Wilson RK; Ley TJ; Graubert TA
Leukemia; 2011 Jul; 25(7):1153-8. PubMed ID: 21415852
[TBL] [Abstract][Full Text] [Related]
35. RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype.
Estécio MR; Maddipoti S; Bueso-Ramos C; DiNardo CD; Yang H; Wei Y; Kondo K; Fang Z; Stevenson W; Chang KS; Pierce SA; Bohannan Z; Borthakur G; Kantarjian H; Garcia-Manero G
Br J Haematol; 2015 May; 169(3):344-51. PubMed ID: 25612675
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.
Falantes JF; Trujillo P; Piruat JI; Calderón C; Márquez-Malaver FJ; Martín-Antonio B; Millán A; Gómez M; González J; Martino ML; Montero I; Parody R; Espigado I; Urbano-Ispizua A; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):236-44. PubMed ID: 25487600
[TBL] [Abstract][Full Text] [Related]
37. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
[TBL] [Abstract][Full Text] [Related]
38. Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS).
Xie X; Frank D; Patnana PK; Schütte J; Al-Matary Y; Liu L; Wei L; Dugas M; Varghese J; Nimmagadda SC; Khandanpour C
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008835
[TBL] [Abstract][Full Text] [Related]
39. Decreased SCIN expression, associated with promoter methylation, is a valuable predictor for prognosis in acute myeloid leukemia.
Zhang ZH; Zhang W; Zhou JD; Zhang TJ; Ma JC; Xu ZJ; Lian XY; Wu DH; Wen XM; Deng ZQ; Lin J; Qian J
Mol Carcinog; 2018 Jun; 57(6):735-744. PubMed ID: 29457658
[TBL] [Abstract][Full Text] [Related]
40. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.
Woo J; Howard NP; Storer BE; Fang M; Yeung CC; Scott BL; Deeg HJ
Haematologica; 2017 Jun; 102(6):e216-e218. PubMed ID: 28209655
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]